Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy

Area of Science:

• Regenerative Medicine
• Cell Biology
• Pulmonary Medicine

Background:

• Cystic fibrosis (CF) results from CFTR gene mutations, with current therapies ineffective for severe expression loss.
• Cell therapy offers a mutation-agnostic treatment strategy for CF.
• Human bronchial epithelial cells (HBECs) are a target for CF cell therapy, requiring extensive expansion while retaining function.

Purpose of the Study:

• To evaluate if conditionally reprogrammed cell (CRC) technology can expand HBECs while preserving CFTR activity.
• To compare NGFR expression and 3D bronchosphere colony-forming efficiency (CFE) between standard and CRC methods.
• To assess cell proliferation and CFTR function in a competitive repopulation assay.

Main Methods:

• HBECs were cultured using standard medium or CRC technology (feeder cells and Rho kinase inhibitor).
• NGFR expression and 3D CFE were assessed in early and late passages.
• Chimeric air-liquid interface cultures were used for competitive repopulation assays to determine cell number and CFTR activity.

Main Results:

• CRC-expanded HBECs showed higher NGFR levels and superior 3D CFE at later passages.
• CRC method resulted in greater cell expansion in chimeric cultures.
• CRC-expanded HBECs demonstrated the most effective reconstitution of CFTR activity.

Conclusions:

• CRC technology enables robust expansion of HBECs with retained capacity for functional CFTR expression.
• This method holds potential for developing effective cell therapies for cystic fibrosis.
• The HBEC air-liquid interface model is a valuable platform for evaluating CF cell therapies.